Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) up 16.2% since last earnings report: Can it continue?

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...
The Motley Fool

Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...
Yahoo Finance

Recursion (RXRX) Up on $50M NVDA Investment for AI Drug Discovery

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq

Expert Outlook: Recursion Pharmaceuticals Through The Eyes Of 4 Analysts

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...
The Motley Fool

Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?

With a one-of-a-kind platform that can run and analyze millions of experiments at a time, Recursion could change the drug-discovery process. The stock market, though, isn't that impressed, and the ...
PharmiWeb

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient ...